Skip to content

This is a promotional website fully funded and created by SERB Pharmaceuticals for UK Healthcare Professionals only.

You are viewing the Voraxaze(glucarpidase) website for the United Kingdom.

Certain BTG products may not be available within the chosen
location, and indications may differ from your country's approved use.

I am a patient

Continue

I am a Healthcare Professional

Outside of the UK

I am a Healthcare Professional
In the UK

UK-VRX-2600029 Date of Last Revision: February 2026

Voraxaze works
in the circulation

Voraxaze® Works in the Circulation to Quickly Clear Methotrexate (MTX)1-3

Voraxaze and Leucovorin Work Differently1,2

  • Voraxaze® (glucarpidase) lowers toxic levels in the extracellular compartment, whereas leucovorin counteracts MTX intracellularly. Only Voraxaze rapidly reduces plasma MTX concentrations by hydrolyzing extracellular MTX
  • Voraxaze rapidly cleaves MTX into 2 inactive metabolites to provide a nonrenal pathway for elimination1,3

VORAXAZE® converts MTX to INACTIVE METABOLITES within 15 minutes1,4

Voraxaze-MOA-molecule_1

Abbreviations: DAMPA, 4-deoxy-4-amino-N10-methylpteroic acid; MTX, methotrexate.

References

  1. Summary of Product Characteristics (SmPC), Voraxaze®
  2. Howard SC, et al. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471-82.
  3. Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006;11(6):694-703.

UK-VRX-2600032 Date of Last Revision: February 2026